Evidence map›Paper›PMID 38500275›Full record

ReviewCurrent drug targets2024

Antiobesity Drug Discovery Research:

Radheshyam, Priyanka Gauniya, Mona Semalty, Ajay Semalty

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

RadheshyamDepartment of Pharmaceutical Sciences, Hemwati Nandan Bahuguna Garhwal University (A Central University) Srinagar (Garhwal), Uttarakhand, India.
Priyanka GauniyaDepartment of Pharmaceutical Sciences, Hemwati Nandan Bahuguna Garhwal University (A Central University) Srinagar (Garhwal), Uttarakhand, India.
Mona SemaltyDepartment of Pharmaceutical Sciences, Hemwati Nandan Bahuguna Garhwal University (A Central University) Srinagar (Garhwal), Uttarakhand, India.
Ajay SemaltyDepartment of Pharmaceutical Sciences, Hemwati Nandan Bahuguna Garhwal University (A Central University) Srinagar (Garhwal), Uttarakhand, India.
Hemwati Nandan Bahuguna Garhwal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a growing global health problem, leading to various chronic diseases. Despite standard treatment options, the prevalence of obesity continues to rise, emphasizing the need for new drugs.

Indexed as

Anti-Obesity AgentsDrug DiscoveryObesityAnimalsDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysHumansAnti-Obesity Agentsantiobesity drugs.BMIcell linesobesity and overweightPancreatic lipase inhibitionpreclinical testsweight management

Identifiers

PMID38500275
OpenAlexW4392966328

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.